Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aligos Therapeutics, Inc. - Common stock
(NQ:
ALGS
)
5.310
-0.010 (-0.19%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aligos Therapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
November 10, 2025
Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodium
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
November 06, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Earnings Scheduled For May 6, 2025
↗
May 06, 2025
Via
Benzinga
Aligos Therapeutics's Earnings Outlook
↗
May 05, 2025
Via
Benzinga
Aligos Therapeutics to Present at Upcoming Investor Conferences
November 04, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
October 30, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 17, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
October 16, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
October 14, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
October 07, 2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
September 03, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 27, 2025
Via
Benzinga
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
August 20, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 15, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
August 13, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
August 06, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
June 18, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
May 20, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 12, 2025
Via
Benzinga
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
May 08, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
May 06, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
